Zhuhai Rundu Pharmaceutical Co (002923) Fair Value & Analysis

Healthcare · CN · Market cap 3.3B CNY

Analysis

Zhuhai Rundu Pharmaceutical Co (002923) currently trades at ¥9.89, while our model-based Fair Value estimate is ¥3.53 — implying the stock looks roughly 64.3% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Zhuhai Rundu Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of chemical pharmaceutical preparations, APIs, and pharmaceutical intermediates in China and internationally. It offers FDF for cardiovascular; and pellets for excipient, antiulcerative, diabetes drug, anti-inflammatory, and anti-anginals. The company is also involved in the process development, quality research, and registration of chemical drugs. In addition, it provides branding services of drug products, as well as academic services. The company was founded in 1999 and is headquartered in Zhuhai, China.

Open the full interactive analysis →

Similar stocks

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.